A detailed history of American Portfolios Advisors transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, American Portfolios Advisors holds 2,044 shares of SUPN stock, worth $73,870. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,044
Holding current value
$73,870
% of portfolio
0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Mar 17, 2023

BUY
$28.79 - $35.41 $58,846 - $72,378
2,044 New
2,044 $69.2 Million
Q2 2022

Mar 20, 2023

BUY
$25.33 - $34.25 $8,333 - $11,268
329 Added 16.1%
2,373 $68.6 Million
Q1 2022

Mar 21, 2023

BUY
$28.51 - $32.9 $8,752 - $10,100
307 Added 15.02%
2,351 $76 Million
Q4 2021

Mar 21, 2023

BUY
$26.37 - $34.22 $4,324 - $5,612
164 Added 8.02%
2,208 $64.4 Million
Q3 2021

Mar 22, 2023

SELL
$23.54 - $31.39 $17,490 - $23,322
-743 Reduced 36.35%
1,301 $34.7 Million
Q2 2021

Mar 22, 2023

SELL
$26.72 - $33.19 $24,074 - $29,904
-901 Reduced 44.08%
1,143 $35.2 Million
Q4 2019

Mar 24, 2023

SELL
$19.93 - $29.13 $32,764 - $47,889
-1,644 Reduced 80.43%
400 $9.49 Million
Q2 2019

Mar 24, 2023

SELL
$29.96 - $38.87 $49,254 - $63,902
-1,644 Reduced 80.43%
400 $13.2 Million
Q1 2019

Mar 24, 2023

BUY
$32.77 - $41.99 $13,108 - $16,796
400 New
400 $14 Million
Q4 2018

Mar 24, 2023

SELL
$30.84 - $49.51 $143,714 - $230,716
-4,660 Closed
0 $0
Q3 2018

Mar 24, 2023

BUY
$42.7 - $56.55 $111,703 - $147,934
2,616 Added 127.98%
4,660 $235 Million
Q2 2018

Mar 24, 2023

BUY
$44.1 - $59.85 $105,310 - $142,921
2,388 Added 116.83%
4,432 $265 Million

Others Institutions Holding SUPN

About SUPERNUS PHARMACEUTICALS, INC.


  • Ticker SUPN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 53,495,300
  • Market Cap $1.93B
  • Description
  • Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...
More about SUPN
Track This Portfolio

Track American Portfolios Advisors Portfolio

Follow American Portfolios Advisors and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of American Portfolios Advisors, based on Form 13F filings with the SEC.

News

Stay updated on American Portfolios Advisors with notifications on news.